glp-1 + nad+ Unlocking Synergy: How Injections Enhance the Effects of Weight Loss Medications What Older Adults Should Know
Description
Since sodium/glucose cotransporter-2 (SGLT-2) inhibitor treatment reduces CV events as well (with the effect mainly driven by a reduction in heart failure complications), the individual risk of ischemic or heart failure complications should guide the choice of treatment
No human safety profile has been established beyond early-phase trials, and this compound is not approved for therapeutic use
No dosage adjustment is needed if changing the injection site and/or timing
Once-Weekly Semaglutide 72 mg in Adults with Obesity (STEP UP)
Notably, tirzepatide may reduce the effectiveness of oral contraceptives during dose escalation due to delayed gastric emptying
